Regulatory T cells in cancer immunotherapy
By Atsushi Tanaka, Shimon Sakaguchi. Cell Research, 2016
1,858 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/b99b45601033b97b4483c38213fc293648110981
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- Atsushi Tanaka
- Naganari Ohkura
- J. Wing
- Ming O. Li
- K. Ichiyama
- N. Mikami
- Wenjun Ouyang
- Christopher Sander
In Oncology
- Atsushi Tanaka
- Christopher Sander
- Zemin Zhang
- Yuanyuan Zhang
- Timothy A. Chan
- Joseph A. Baur
- Douglas C. Wallace
- Shimon Sakaguchi
Citations in the corpus
- Foxp3 reprograms T cell metabolism to function in low glucose high lactate environments (2017, background): “Tregs accumulate in the tumor microenvironment and are increasingly recognized as a therapeutic target in cancer immunotherapy (Nishikawa and Sakaguchi, 2014).”
- Acute pharmacological degradation of Helios destabilizes regulatory T cells (2021, positive): “Regulatory T cells (Tregs) are a specialized subset of CD4+ T cells that maintain normal immune tolerance and homeostasis but also repress the anti-tumor immune response 1,2 .”
- Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment (2019, background): “Given that Tregs suppress the effector function of various immune cells, they can also inhibit immune responses against cancer cells and thus promote tumor growth (6).”
- Regulatory T Cells and Human Disease. (2020, background): “Cancertissue-infiltrating FOXP3+ T cells are predominantly FOXP3high effector Tregs in a majority of cancers (140).”
- Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. (2017, positive): “Although the clinical efficacy of various checkpoint inhibitors hinges at least in part upon their ability to unleash the CD8 cytotoxic T cells in the tumor microenvironment, the cytotoxic activity of these T cells could be rendered ineffective primarily by the suppression of Tregs (Nishikawa and Sa”
- IDO in the Tumor Microenvironment: Inflammation, Counter-regulation and Tolerance (2016, neutral): “Regulatory T cells are a major suppressive mechanism in tumors [79].”
- Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures (2016, background): “latory T cells (Tregs) and tumor associated macrophages (TAMs) have been associated with pro-tumor functions [1–3], whereas CD8 T cells have been associated with”
- Regulatory T cells exhibit distinct features in human breast cancer (2016, neutral): “Treg cells have also been found in increased numbers in diverse experimental mouse tumors and in human cancers (Nishikawa and Sakaguchi, 2014; Roychoudhuri et al., 2015).”
- Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives (2021, background): “Treg cells with high Foxp3 expression are known to have crucial functions in the restriction of antitumor immunity [207].”
- Therapeutic cancer vaccines. (2010, background): “These mechanisms include checkpoint suppression of T cells (4–6, 50, 99–101), Tregs (102), myeloid-derived suppressor cells (MDSCs) (103, 104), immunosuppressive cytokines such as TGF-β (105, 106) and IL-10 (107–109), and indoleamine 2,3-dioxygenase (IDO) (110–112), as well as lack of T cell infiltr”